A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

Alexander D. Douglas (), G. Christian Baldeviano, Jing Jin, Kazutoyo Miura, Ababacar Diouf, Zenon A. Zenonos, Julio A. Ventocilla, Sarah E. Silk, Jennifer M. Marshall, Daniel G. W. Alanine, Chuan Wang, Nick J. Edwards, Karina P. Leiva, Luis A. Gomez-Puerta, Carmen M. Lucas, Gavin J. Wright, Carole A. Long, Joseph M. Royal and Simon J. Draper ()
Additional contact information
Alexander D. Douglas: Old Road Campus Research Building
G. Christian Baldeviano: US Naval Medical Research Unit No. 6 (NAMRU-6)
Jing Jin: Old Road Campus Research Building
Kazutoyo Miura: Laboratory of Malaria and Vector Research, NIAID/NIH
Ababacar Diouf: Laboratory of Malaria and Vector Research, NIAID/NIH
Zenon A. Zenonos: Wellcome Trust Sanger Institute
Julio A. Ventocilla: US Naval Medical Research Unit No. 6 (NAMRU-6)
Sarah E. Silk: Old Road Campus Research Building
Jennifer M. Marshall: Old Road Campus Research Building
Daniel G. W. Alanine: Old Road Campus Research Building
Chuan Wang: Old Road Campus Research Building
Nick J. Edwards: Old Road Campus Research Building
Karina P. Leiva: US Naval Medical Research Unit No. 6 (NAMRU-6)
Luis A. Gomez-Puerta: US Naval Medical Research Unit No. 6 (NAMRU-6)
Carmen M. Lucas: US Naval Medical Research Unit No. 6 (NAMRU-6)
Gavin J. Wright: Wellcome Trust Sanger Institute
Carole A. Long: Laboratory of Malaria and Vector Research, NIAID/NIH
Joseph M. Royal: US Naval Medical Research Unit No. 6 (NAMRU-6)
Simon J. Draper: Old Road Campus Research Building

Nature Communications, 2019, vol. 10, issue 1, 1-8

Abstract: Abstract Malaria vaccine design and prioritization has been hindered by the lack of a mechanistic correlate of protection. We previously demonstrated a strong association between protection and merozoite-neutralizing antibody responses following vaccination of non-human primates against Plasmodium falciparum reticulocyte binding protein homolog 5 (PfRH5). Here, we test the mechanism of protection. Using mutant human IgG1 Fc regions engineered not to engage complement or FcR-dependent effector mechanisms, we produce merozoite-neutralizing and non-neutralizing anti-PfRH5 chimeric monoclonal antibodies (mAbs) and perform a passive transfer-P. falciparum challenge study in Aotus nancymaae monkeys. At the highest dose tested, 6/6 animals given the neutralizing PfRH5-binding mAb c2AC7 survive the challenge without treatment, compared to 0/6 animals given non-neutralizing PfRH5-binding mAb c4BA7 and 0/6 animals given an isotype control mAb. Our results address the controversy regarding whether merozoite-neutralizing antibody can cause protection against P. falciparum blood-stage infections, and highlight the quantitative challenge of achieving such protection.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-09894-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09894-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-09894-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().